The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
September 4, 2023
View Complete Issue         Table of Contents 2019 
Niraparib/Abiraterone Acetate (Akeega) for Prostate Cancer (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Niraparib/Abiraterone Acetate (Akeega) for Prostate Cancer (online only)
September 4, 2023 (Issue: 1684)
Akeega (Janssen), a fixed-dose combination of the oral poly(ADP-ribose) polymerase (PARP) inhibitor niraparib (Zejula) and the antiandrogen abiraterone acetate (Zytiga, and others), has been approved by the FDA for use in combination...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Niraparib/Abiraterone Acetate (Akeega) for Prostate Cancer (online only)
Article code: 1684c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.